🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to scientists.

An International Health Concern

Gonorrhoea infections are escalating around the world, with data suggesting more than 82 million instances per year. Notably increased rates are seen in the African continent and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce treatment choices currently available.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Secure Authorization

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers hope that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in concurrent days. This medication, which is also used to treat urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP collaborated with the drug firm its industry partner to see it through.

“This approval marks a significant shift in the therapy of multidrug-resistant gonorrhoea, which previously has been outpacing medical innovation.”

Testing Outcomes and Global Access

Based on results detailed in a prominent scientific publication, the new drug successfully treated more than 90% of uncomplicated infections. This places it at an comparable level with the current standard treatment, which uses a dual-drug approach. The trial included over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the ability to make available and distribute the drug in many developing nations.

Clinicians directly involved have expressed optimism. The availability of a easy-to-administer therapy of this kind is described as a "critical tool" for managing the epidemic. This is considered essential to lessen the impact of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea worldwide.